THE BOTTOM LINE
- National Rules Can Override EU Free Trade: This ruling confirms that Member States can impose stricter national product standards, even if it restricts the free movement of goods, provided it’s justified by a scientifically-backed public health risk.
- Scientific Uncertainty Favors Regulators: Companies face an uphill battle when scientific consensus is divided. The court affirmed the government’s right to apply the precautionary principle, meaning that even a potential or uncertain risk can be enough to justify a market ban.
- Market-Specific Compliance is Non-Negotiable: A product being legal in one EU country is no guarantee of access to another. Businesses must actively assess and comply with the specific health regulations and risk assessments of each target market, which often consider local dietary habits.
THE DETAILS
The case centered on a classic conflict within EU law: the fundamental principle of free movement of goods versus a Member State’s authority to protect public health. The company, Solgar Vitamins, sought to sell a 100 microgram (µg) Vitamin D supplement, a product lawfully sold in other EU markets. However, Dutch law sets a maximum daily dose of 75 µg for such supplements. The Dutch government denied Solgar’s request for an exemption, leading to the legal challenge. The District Court of Rotterdam acknowledged that the Dutch rule created a trade barrier but focused on whether this barrier was legally justified under Article 36 of the TFEU.
The court ultimately sided with the Dutch government, finding the restriction was a necessary and proportionate measure to protect public health. The decision rested heavily on scientific risk assessments from the European Food Safety Authority (EFSA), which established a Tolerable Upper Intake Level (UL) of 100 µg of Vitamin D per day from all sources, including food. The government successfully argued that allowing a 100 µg supplement would inevitably cause consumers to exceed this safe daily limit once their regular dietary intake was factored in. The court held that this constituted a real risk to public health, not merely a hypothetical one, validating the government’s use of the precautionary principle.
Crucially, the court found the government’s complete ban on the 100 µg product to be a proportional response. Solgar suggested that a less restrictive measure, such as a warning label, would suffice. The court rejected this, agreeing with the government that labeling would be ineffective. The court reasoned that it is impractical for the average consumer to accurately track and calculate their total daily Vitamin D intake from various foods. Therefore, a clear maximum limit in supplements was deemed the only effective way to prevent excessive consumption and its associated health risks, such as hypercalcemia. For businesses, this decision underscores that simply clearing regulatory hurdles in one EU country does not grant a passport to the entire single market, especially in health-sensitive sectors.
SOURCE
Rechtbank Rotterdam
